JP2022530051A5 - - Google Patents
Info
- Publication number
- JP2022530051A5 JP2022530051A5 JP2021562991A JP2021562991A JP2022530051A5 JP 2022530051 A5 JP2022530051 A5 JP 2022530051A5 JP 2021562991 A JP2021562991 A JP 2021562991A JP 2021562991 A JP2021562991 A JP 2021562991A JP 2022530051 A5 JP2022530051 A5 JP 2022530051A5
- Authority
- JP
- Japan
- Prior art keywords
- oxadiazole
- pharmaceutically acceptable
- optionally substituted
- tautomer
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19170502 | 2019-04-23 | ||
| EP19170502.9 | 2019-04-23 | ||
| PCT/EP2020/061148 WO2020216764A1 (en) | 2019-04-23 | 2020-04-22 | Modulators of the integrated stress response pathway |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530051A JP2022530051A (ja) | 2022-06-27 |
| JP2022530051A5 true JP2022530051A5 (https=) | 2023-04-27 |
| JP7588089B2 JP7588089B2 (ja) | 2024-11-21 |
Family
ID=66248567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562991A Active JP7588089B2 (ja) | 2019-04-23 | 2020-04-22 | 統合ストレス応答経路のモジュレーター |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220213078A1 (https=) |
| EP (1) | EP3959210A1 (https=) |
| JP (1) | JP7588089B2 (https=) |
| CN (1) | CN114008041A (https=) |
| AU (1) | AU2020262153B2 (https=) |
| BR (1) | BR112021020106A2 (https=) |
| CA (1) | CA3137212A1 (https=) |
| EA (1) | EA202192900A1 (https=) |
| IL (1) | IL287378B2 (https=) |
| MX (1) | MX2021012904A (https=) |
| SG (1) | SG11202111362SA (https=) |
| WO (1) | WO2020216764A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019118785A2 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| MX2022011143A (es) | 2020-03-11 | 2022-10-13 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| JP2023546224A (ja) | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合ストレス応答経路のモジュレーター |
| MX2023004623A (es) | 2020-10-22 | 2023-05-12 | Evotec Int Gmbh | Moduladores de la via integrada de respuesta al estres. |
| WO2024109736A1 (zh) * | 2022-11-21 | 2024-05-30 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其合成方法和用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014229283B2 (en) * | 2013-03-14 | 2016-07-28 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| TWI763668B (zh) | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| CA3026982A1 (en) | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| AU2017279027A1 (en) | 2016-06-08 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CN110896634A (zh) | 2017-07-03 | 2020-03-20 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物 |
| US20210145771A1 (en) | 2017-07-03 | 2021-05-20 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CN118239937A (zh) | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| DK3676297T3 (da) * | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3704125B1 (en) | 2017-11-02 | 2026-03-11 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| SG11202004009TA (en) | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| EP3704096B1 (en) | 2017-11-02 | 2026-04-22 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| EP3704098B1 (en) | 2017-11-02 | 2024-01-24 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| CA3080804A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| WO2019118785A2 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| US20220177456A1 (en) * | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3137213A1 (en) * | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| MX2022011143A (es) * | 2020-03-11 | 2022-10-13 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
-
2020
- 2020-04-22 MX MX2021012904A patent/MX2021012904A/es unknown
- 2020-04-22 BR BR112021020106A patent/BR112021020106A2/pt unknown
- 2020-04-22 IL IL287378A patent/IL287378B2/en unknown
- 2020-04-22 US US17/605,369 patent/US20220213078A1/en active Pending
- 2020-04-22 AU AU2020262153A patent/AU2020262153B2/en active Active
- 2020-04-22 CA CA3137212A patent/CA3137212A1/en active Pending
- 2020-04-22 CN CN202080046012.1A patent/CN114008041A/zh active Pending
- 2020-04-22 WO PCT/EP2020/061148 patent/WO2020216764A1/en not_active Ceased
- 2020-04-22 JP JP2021562991A patent/JP7588089B2/ja active Active
- 2020-04-22 EA EA202192900A patent/EA202192900A1/ru unknown
- 2020-04-22 EP EP20719209.7A patent/EP3959210A1/en active Pending
- 2020-04-22 SG SG11202111362SA patent/SG11202111362SA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022530051A5 (https=) | ||
| JP2022530049A5 (https=) | ||
| JP2023511616A5 (https=) | ||
| JP2023517944A5 (https=) | ||
| JP2019077725A5 (https=) | ||
| JP2014525444A5 (https=) | ||
| JP2024522494A5 (https=) | ||
| JP2014521653A5 (https=) | ||
| JP2023506642A5 (https=) | ||
| JP2017193592A5 (https=) | ||
| HRP20191327T1 (hr) | 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja | |
| RU2006136881A (ru) | Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv | |
| JP2020516671A5 (https=) | ||
| HRP20191140T1 (hr) | Spojevi i pripravci kao inhibitori c-kit kinaze | |
| JP2014526501A5 (https=) | ||
| JP2012525349A5 (https=) | ||
| JP2022552444A5 (https=) | ||
| JP2017505762A5 (https=) | ||
| JP2013528204A5 (https=) | ||
| JP2011517457A5 (https=) | ||
| JP2016537389A5 (https=) | ||
| JP2023521351A5 (https=) | ||
| JP2017508766A5 (https=) | ||
| JP2021500340A5 (https=) | ||
| JP2014523400A (ja) | 芳香族アミド類およびそれらの使用 |